Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 9/20 | 0.59 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | CCR5 | P51681 | 2/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20187161 | 0.90 | DDR1 (0.59) | DDR1NPC1L1USP30HRH3CCR5 | |
| SCHEMBL20187038 | 0.88 | DDR1 (0.60) | DDR1NPC1L1USP30HRH3CCR5 | |
| SCHEMBL20187028 | 0.88 | DDR1 (0.61) | DDR1NPC1L1USP30HRH3CCR5 | |
| SCHEMBL20187112 | 0.87 | DDR1 (0.55) | DDR1NPC1L1USP30CCR5ENPP2 | |
| SCHEMBL319067 | 0.79 | NPC1L1 (0.55) | DDR1NPC1L1USP30CCR5 | |
| SCHEMBL20187089 | 0.78 | DDR1 (0.58) | DDR1HRH3ENPP2 | |
| SCHEMBL17140692 | 0.78 | NPC1L1 (0.58) | NPC1L1USP30CCR5ENPP2 | |
| SCHEMBL7845129 | 0.78 | NPC1L1 (0.58) | DDR1NPC1L1USP30CCR5 | |
| SCHEMBL17140752 | 0.78 | NPC1L1 (0.48) | DDR1NPC1L1USP30CCR5ENPP2 | |
| SCHEMBL12338068 | 0.78 | OPRM1 (0.59) | DDR1NPC1L1USP30CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107849044-B | Triaza-spirodecanones as DDR1 inhibitors | 豪夫迈·罗氏有限公司 | 2021-06-25 | — | — | CN | disclosed |
| EP-3317279-B1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-10435407-B2 | Triaza-spirodecanones as DDR1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190169189-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-06-06 | — | — | US | disclosed |
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | HOFFMAN LA-ROCHE INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA-ROCHE INC. (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169189-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | DDR1 1/4885NPC1L1 3430/4885USP30 3051/4885 |
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | DDR1 1/4885NPC1L1 3430/4885USP30 3051/4885 |
| US-10435407-B2 | Triaza-spirodecanones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | DDR1 1/4885NPC1L1 3430/4885USP30 3051/4885 |
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | DDR1 1/4885NPC1L1 3430/4885USP30 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.